IFNA1 and melanoma: Shing et al. discovered that loss of function mutations in JAK1/2 in melanoma cells could inhibit T cells killing capacity and IFN’s ability to induce PD-L1 expression, making pharmacological suppression of the PD-L1/PD-1 interaction ineffective.